These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 17196075)

  • 41. Fluticasone propionate/formoterol fumarate in fixed-dose combination for the treatment of asthma.
    Price D; Hillyer EV
    Expert Rev Respir Med; 2014 Jun; 8(3):275-91. PubMed ID: 24802285
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Aerodynamic particle size analysis of aerosols from pressurized metered-dose inhalers: comparison of Andersen 8-stage cascade impactor, next generation pharmaceutical impactor, and model 3321 Aerodynamic Particle Sizer aerosol spectrometer.
    Mitchell JP; Nagel MW; Wiersema KJ; Doyle CC
    AAPS PharmSciTech; 2003 Oct; 4(4):E54. PubMed ID: 15198549
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Total reversibility testing as indicator of the clinical efficacy of formoterol in COPD.
    Molimard M; Bourcereau J; Le Gros V; Bourdeix I
    Respir Med; 2005 Jun; 99(6):695-702. PubMed ID: 15878485
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of formoterol/budesonide combination on arterial blood gases in patients with acute exacerbation of COPD.
    Cazzola M; Noschese P; De Michele F; D'Amato G; Matera MG
    Respir Med; 2006 Feb; 100(2):212-7. PubMed ID: 15936184
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Insulin-micro- and nanoparticles for pulmonary delivery.
    Klingler C; Müller BW; Steckel H
    Int J Pharm; 2009 Jul; 377(1-2):173-9. PubMed ID: 19446621
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease.
    Rosenkranz B; Rouzier R; Kruse M; Dobson C; Ayre G; Horowitz A; Fitoussi S
    Respir Med; 2006 Apr; 100(4):666-72. PubMed ID: 16303295
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of patient-reported outcomes during treatment with adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler versus fixed-dose fluticasone propionate/salmeterol dry powder inhaler in patients with asthma.
    O'Connor RD; Patrick DL; Parasuraman B; Martin P; Goldman M
    J Asthma; 2010 Mar; 47(2):217-23. PubMed ID: 20170333
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Use of formoterol dry powder administered for three months via a single-dose inhaler in 1,380 asthmatic patients.
    Clauzel AM; Molimard M; Le Gros V; Lepère E; Febvre N; Michel FB
    J Investig Allergol Clin Immunol; 1998; 8(5):265-70. PubMed ID: 9827420
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Onset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPD.
    Cazzola M; Centanni S; Regorda C; di Marco F; di Perna F; Carlucci P; Boveri B; Santus P
    Pulm Pharmacol Ther; 2001; 14(1):41-5. PubMed ID: 11162418
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Performance of large- and small-volume valved holding chambers with a new combination long-term bronchodilator/anti-inflammatory formulation delivered by pressurized metered dose inhaler.
    Nagel MW; Wiersema KJ; Bates SL; Mitchell JP
    J Aerosol Med; 2002; 15(4):427-33. PubMed ID: 12581509
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Can low-dose combination products for inhalation be formulated in single crystalline particles?
    Kumon M; Kwok PC; Adi H; Heng D; Chan HK
    Eur J Pharm Sci; 2010 Apr; 40(1):16-24. PubMed ID: 20172026
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lung function and asthma control with beclomethasone and formoterol in a single inhaler.
    Huchon G; Magnussen H; Chuchalin A; Dymek L; Gonod FB; Bousquet J
    Respir Med; 2009 Jan; 103(1):41-9. PubMed ID: 18977646
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Selecting an accessory device with a metered-dose inhaler: variable influence of accessory devices on fine particle dose, throat deposition, and drug delivery with asynchronous actuation from a metered-dose inhaler.
    Wilkes W; Fink J; Dhand R
    J Aerosol Med; 2001; 14(3):351-60. PubMed ID: 11693847
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of maximum inhalation flow and inhaled volume on formoterol drug deposition in-vitro from an Easyhaler® dry powder inhaler.
    Abadelah M; Hazim F; Chrystyn H; Bagherisadeghi G; Rahmoune H; Larhrib H
    Eur J Pharm Sci; 2017 Jun; 104():180-187. PubMed ID: 28351669
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and tolerability of high-dose formoterol (Aerolizer) and salbutamol (pMDI) in patients with mild/moderate, persistent asthma.
    Kruse M; Rosenkranz B; Dobson C; Ayre G; Horowitz A
    Pulm Pharmacol Ther; 2005; 18(3):229-34. PubMed ID: 15707858
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Profiles of measured and perceived bronchodilation. A placebo-controlled cross-over trial comparing formoterol and salmeterol in moderate persistent asthma.
    Schermer TR; Hoff WJ; Greefhorst AP; Creemers JP; Sips AP; Westbroek J; van Herwaarden CL
    Pulm Pharmacol Ther; 2004; 17(4):205-12. PubMed ID: 15219265
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bronchodilation and bronchoprotection in asthmatic preschool children from formoterol administered by mechanically actuated dry-powder inhaler and spacer.
    Nielsen KG; Bisgaard H
    Am J Respir Crit Care Med; 2001 Jul; 164(2):256-9. PubMed ID: 11463597
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In-vitro characterisation of metered dose inhaler versus dry powder inhaler glucocorticoid products: influence of inspiratory flow rates.
    Feddah MR; Brown KF; Gipps EM; Davies NM
    J Pharm Pharm Sci; 2000; 3(3):318-24. PubMed ID: 11177650
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Budesonide/formoterol in a single inhaler rapidly relieves methacholine-induced moderate-to-severe bronchoconstriction.
    van der Woude HJ; Boorsma M; Bergqvist PB; Winter TH; Aalbers R
    Pulm Pharmacol Ther; 2004; 17(2):89-95. PubMed ID: 15123230
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD.
    Richter K; Stenglein S; Mücke M; Sieder C; Schmidtmann S; Harnest U; Weidinger G; Magnussen H
    Respiration; 2006; 73(4):414-9. PubMed ID: 16534180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.